



President's Message

Dear colleagues,

Welcome back from ASCO as we look forward to the summer months where we hopefully can take advantage of some Vitamin D. Time for the summer newsletter to let you know what has happened and is happening at CAMO. The Executive, Dr. Desiree Hao (President-Elect), Dr. Hal Hirte (Past President), Dr. Sharlene Gill (Secretary-Treasurer) and myself, Dr. Bruce Colwell (President) have been busy trying to make this organization bigger, better and most importantly more relevant. We have been contacting people to sit on a number of committees and will continue to call on you.

The CAMO Annual Scientific Meeting was held in the MaRS Center in Toronto, ON this year. It was a fantastic venue, offering great space for posters, networking breaks and the main plenary. The modern and clean space also offered a great AV and catering service. We will definitely try to book the space for 2020! The attendance was down a little from last year when we had a record number of posters but we attribute that to the change in exam schedules for both PGY3 and 4's this year. I suspect with the format of the Royal College exams in the PGY3 year we will have a lot more posters next year. It was expertly chaired by Dr. Samantha Gray from Saint John and Dr. Lacey Pitre from Sudbury. We started out with 8 oral presentations from across the country. Dr. Neil Reaume then introduced some of us and reinforced with some the role of social media in oncology. I have created a @CAMOPREZ twitter handle and I am trying to tweet some information and retweet lots from some of the more active oncology tweeters out there. I plan to hand this on to Desiree after the meeting next year and get my own handle. Till then I am @CAMOPREZ. After lunch, we had a fantastic panel discussion from an endocrinologist, a rheumatologist, a respirologist and gastroenterologist talking about handling some of the toxicities of the new immune-oncology drugs. They were extremely informative. Dr. James Douketis then updated us on thrombosis in malignancy prior to the lightning round of 6 poster presentations. The evening ended with the pioneer lecture by a very familiar face, Dr. Elizabeth Eisenhauer. She honored us with a review of 35 years of cancer research. We have also been collaborating with other groups during the CAMO ASM: Oncology Education had their Wednesday evening symposium and new this year we also partnered with WinC who hosted a Friday evening symposium.

As you heard last year, the CPD committee was working on becoming a Royal College accredited CPD provider and we have been successful with our second application! If you are looking at having a program accredited, please visit the new professional development section of the CAMO website. Dr. Ghazaleh Kazemi and her committee have done a lot of work to get this done. It is similar to the process when a training program gets its accreditation status renewed. New this year during the 2019 ASM, we had our first session offering section 3 CME credits to participants.

We also have been approached by a medical journal for collaboration, which may allow CAMO members a discount in the future for publications. Stay tuned for more information.

The Human Resources Committee, chaired by Dr. Desiree Hao met in Toronto before the ASM and has plans to look at revising some of the work done in the past looking at medical oncology manpower.

The most recent project that we are about to launch is Find an Oncologist. This search engine will allow everyone (public, members, patients, etc.) to find the nearest oncologist that treats a specific cancer type. An email will be sent to CAMO members with specific instructions.

I wish you all a fantastic summer!

Bruce Colwell

Dr. Bruce Colwell MD FRCP(C)
CAMO President

Inside this issue:

Annual Meeting Highlights | p.5

Fellowship Recipient | p.7

CADTH Update | p.8

Important Dates | p.10



Message du président

Chers collègues,

Suite à la réunion de l'ASCO, c'est avec plaisir que nous anticipons l'été qui, à souhaiter, nous réapprovisionnera en vitamine D. Ce bulletin de l'été vous informe de ce qui s'est passé et de ce qui se passe à l'ACOM. Le Comité directeur, formé par la Dre Desiree Hao (Présidente désignée), le Dr Hal Hirte (Président sortant), la Dre Sharlene Gill (Secrétaire-trésorière) et moi-même, Dr Bruce Colwell (Président), s'est efforcé activement de faire croître notre organisation, l'améliorer et, surtout, la rendre plus pertinente. Nous avons invité certaines personnes à siéger sur divers comités et nous continuerons à faire appel à nos membres à cette fin.

La Réunion annuelle scientifique (RAS) 2019 de l'ACOM s'est tenue au centre MaRS à Toronto, en Ontario : un magnifique site moderne et propre offrant beaucoup d'espace pour les affiches, les pauses de réseautage et la séance plénière principale, ainsi qu'un excellent service d'audiovisuel et de traiteur. Nous tenterons très certainement de réserver l'endroit pour 2020! La participation était légèrement inférieure à celle de l'an dernier où nous avons une quantité record d'affiches, ce que nous attribuons à la modification des horaires d'examens chez les AP-3 et 4 cette année. Compte tenu du format des examens du Collège royal à l'année postdoctorale 3, je crois que nous aurons beaucoup plus d'affiches l'an prochain. Animée avec brio par la Dre Samantha Gray de Saint John et la Dre Lacey Pitre de Sudbury, la Réunion a démarré avec huit présentations orales provenant des quatre coins du pays. Puis, le Dr Neil Reaume a traité du rôle des médias sociaux en oncologie, présentant à la fois une introduction et un approfondissement de leur utilité. J'ai créé le pseudo Twitter @CAMOPREZ et j'essaie de « tweeter » de l'information et de réacheminer une mine de renseignements des gazouilleurs les plus actifs du monde de l'oncologie. Je prévois transférer cette tâche à Desiree après la réunion de l'an prochain et créer mon propre pseudo. D'ici-là, je suis @CAMOPREZ. Après le dîner, nous avons eu droit à un superbe débat d'experts, dont un endocrinologue, un rhumatologue, un pneumologue et un gastroentérologue, qui ont abordé la prise en charge des toxicités des nouveaux médicaments immuno-oncologiques. La discussion était extrêmement informative. Puis, le Dr James Douketis a offert une mise à jour sur la thrombose en présence de malignité avant les six présentations éclair par affiches.

La soirée s'est terminée avec la conférence des pionniers, donnée par un visage très familier. La Dre Elizabeth Eisenhauer a présenté un survol de 35 ans de recherche sur le cancer. Nous avons aussi collaboré avec d'autres groupes durant la RAS de l'ACOM : Oncology Education y a tenu son symposium du mercredi soir et, nouvellement cette année, nous avons créé un partenariat avec WinC qui a animé un symposium le vendredi soir.

Comme vous l'avez appris l'an dernier, le Comité du DPC s'employait à faire de l'ACOM un fournisseur de DPC agréé par le Collège royal et notre deuxième demande a été accueillie avec succès! Si vous souhaitez faire agréer un programme, veuillez consulter la nouvelle section de développement professionnel sur le site Web de l'ACOM. La Dre Ghazaleh Kazemi et son comité ont travaillé très fort à ce processus, qui ressemble au renouvellement du statut d'agrément d'un programme de formation. Autre nouveauté durant la RAS 2019 de l'ACOM : notre première séance qui offrait des crédits de FMC de section 3 aux participants.

Nous avons également été invités à collaborer avec une revue médicale, ce qui pourrait entraîner une réduction des coûts de publication pour les membres de l'ACOM à l'avenir. Restez à l'écoute pour plus de détails.

Le Comité des ressources humaines, présidé par la Dre Desiree Hao, s'est réuni à Toronto avant la RAS et il prévoit se pencher sur le travail effectué par le passé en matière de main-d'œuvre en oncologie médicale.

Nous sommes sur le point de lancer notre plus récent projet, « trouver un oncologue ». Il s'agit d'un moteur de recherche qui permettra à quiconque (public, membres, patients, etc.) de trouver l'oncologue le plus près qui traite une forme de cancer spécifique. Les membres de l'ACOM recevront un courriel qui renferme des instructions précises à cet effet.

Je vous souhaite tous et toutes un magnifique été!

Bruce Colwell

Dr. Bruce Colwell MD FRCP(C)
Président, ACOM

HIGHLIGHTS

CAMO 2019 Annual Scientific Meeting | May 2 | Toronto, ON

The Annual Scientific Meeting of the Canadian Association of Medical Oncologists was held on Thursday, May 2, 2019 in Toronto, ON. We welcomed 100 attendees from across Canada. Three major sessions were held including the CAMO Keynote Speaker, the CAMO Symposium and the Pioneers in Canadian Oncology Lecture Series.

**“IN
SEARCH OF
THE BEST
SUPPORT”**

Highlights of the meeting included the CAMO Keynote speaker by **Dr. Neil Reaume** who presented a lecture entitled **“TECHNOLOGY/SOCIAL MEDIA”**.

The afternoon symposium highlighted a panel discussion led by **Dr. Andrew Robinson: Dr. Josh Lakoff, Dr. Alexandre Nelson, Dr. Janet Roberts & Dr. Harminder Singh** shared their knowledge on **“IMMUNO-ONCOLOGY CASES”** and **Dr. James Douketis** was the final speaker and presented a talk on **“UPDATE ON THROMBOSIS IN MALIGNANCY”**.



AWARDS DINNER

In addition to an intense full day symposium, the 2019 CAMO Awards Dinner was held at the Ontario Heritage Trust on Thursday, May 2, 2019. CAMO members enjoyed mingling with their colleagues and listening to the Pioneer Lecture.

The CAMO Pioneers in Canadian Oncology Lecture Series was created to pay tribute to



Canadian pioneers in the field of oncology. The highlight of the evening was the CAMO Pioneer Lecture Series Award Presentation, which was awarded to **Dr. Elizabeth Eisenhauer** who delivered the Pioneer Lecture entitled **“Improved Cancer Outcomes – But Miles to go Before we Sleep: Personal Reflections on 35 Years of Cancer Research”**.



2019 ABSTRACT AWARDS

This year, 27 abstract submissions were received, of which 17 were poster presentations (6 mini-orals) and 8 were oral presentations. Participants were able to circulate during breaks and lunchtime to view all of the poster submissions.

The 2019 abstract awards were presented by Dr. Samantha Gray & Dr. Lacey Pitre.

FIRST place was awarded to **Dr. Shaan Dudani** for her abstract entitled “**FIRST-LINE (1L) IMMUNO-ONCOLOGY (IO) COMBINATION THERAPIES IN METASTATIC RENAL CELL CARCINOMA (MRCC): PRELIMINARY RESULTS FROM THE INTERNATIONAL METASTATIC RENAL CELL CARCINOMA DATABASE CONSORTIUM (IMDC)**”.

SECOND place was awarded to **Dr. Elizabeth Faour** for her abstract entitled “**BARRIERS TO ACCESSING HEALTHCARE SERVICES: A MULTIDISCIPLINARY APPROACH TOWARDS IMPROVING PANCREATIC CANCER SURVIVAL IN A CANADIAN PROVINCE**”.

THIRD place was awarded to **Dr. Michael Raphael** (best poster) for his abstract entitled “**DELIVERY OF BLEOMYCIN AMONG PATIENTS WITH TESTICULAR CANCER: A POPULATION-BASED STUDY OF PULMONARY MONITORING AND TOXICITY**”.



THANK YOU TO OUR 2019 ANNUAL MEETING SPONSORS!



Gold: *Astellas Pharma Canada*

Silver: *Amgen Canada Inc., Merck Canada Inc., Mylan Pharmaceuticals ULC.*

Bronze: *Apobiologix., Ipsen Biopharmaceuticals Canada Inc., Hoffman-La Roche Limited, Pfizer Canada Inc.,*

2019 FELLOWSHIP RECIPIENT

Congratulations to the following recipient of the 2019 CAMO Fellowship:
Dr. Lawson Eng for his project “**ACUTE CARE USE AND OUTCOMES OF IMMUNE-RELATED ADVERSE EVENTS (IRAES) DURING IMMUNOTHERAPY**”.

The Canadian Association of Medical Oncologists gratefully acknowledges the continued support of the fellowship program: Hoffman-La Roche & Pfizer



THANK YOU TO THE FOLLOWING CAMO MEMBERS FOR THEIR GENEROUS DONATIONS TO THE FELLOWSHIP FUND:

Olexiy Aseyev
Sukhbinder Dhesy-Thind
Hal Hirte
Kara Laing
Mary MacNeil
Elaine McWhirter
Callista Phillips

Lacey Pitre
Kylea Potvin
Erin Powell
Neil Reaume
Michael Thirlwell
Stephen Welch
Renaud Whittom

Clinician involvement with CADTH's pan-Canadian Oncology Drug Review Program

CADTH is an independent, not-for-profit organization responsible for providing evidence to inform health care decisions on the optimal use of drugs and devices. With the rapid growth of the pipeline of cancer drugs, CADTH's pan-Canadian Oncology Drug Review (pCODR) program plays an important role supporting the decision-making process for publicly funded cancer drugs in Canada.

"Participation in the pCODR drug review process provides insights into how drugs are evaluated for funding in Canada and an opportunity to influence the outcome of the decision making process."

Dr. Bill Evans, Past President, Canadian Association of Medical Oncologists

Two Ways that Clinicians Can Engage in the pCODR Process

1. Involvement in pCODR Clinical Guidance Panels

Since its inception, pCODR has engaged oncologists from across Canada to generate high quality clinical and economic reviews for cancer drug submissions. Oncologists who participate on a Clinical Guidance Panel (CGP) are recognized as experts in the treatment of a specific tumour type. As of March 31, 2019, pCODR has reviewed 161 drug submissions each with a panel of experts of 3-5 clinicians.




Figure 1 pCODR Submissions Received by Tumour Type

2. Register to Provide Clinician Input and Feedback

pCODR invites practicing clinicians to provide input by providing practice-based contextual information on use of therapies in real world patient populations. This provides greater insight into the value of a particular drug and its place in therapy, as well as helping to identify local implementation challenges.

Clinicians who provide input on a review are also invited to provide feedback on the initial recommendation issued by the pCODR Expert Review Committee (pERC). The pERC members reviews all of the feedback from all stakeholders before issuing a final recommendation. As of March 31, 2019, 273 clinicians have registered to provide input and feedback.

"Clinician expertise and insight are valued inputs in the pCODR drug review process. We would encourage all clinicians to participate either individually or as a group."

Dr. Maureen Trudeau, Chair, pCODR Expert Review Committee

Clinician involvement with CADTH's pan-Canadian Oncology Drug Review Program

Clinician Impact on pERC Recommendations

The conclusions of the CGP and input from registered clinicians are considered by pERC, in addition to the input received from patients, health economists and those managing provincial cancer drug programs to inform its funding recommendations. Since its implementation in July 2011, close to 80% of the 96 positive and conditional pERC recommendations have been adopted by one or more participating jurisdictions.

CADTH continues to evolve how clinicians are involved in the pCODR process. Recently, a [proposal](#) was made to transition some of the implementation functions of CAPCA's Cancer Drug Implementation Advisory Committee to CADTH.

**Interested in contributing your expertise to pCODR?
Learn more at: cadth.ca/pcodr/clinician-input-and-feedback**

If you have questions, please contact Dolly Han, Specialist, at pCODR, at dollyh@cadth.ca for further information.



**CCTG 2019 Biennial New Investigator
Clinical Trials Course**

August 7-9, 2019 | Kingston, ON

CSIM 2019 Annual Meeting

October 2-5, 2019 | Halifax, NS

2019 CANPROS Conference

November 13-15, 2019 | Calgary, AB

ESMO 2019 Congress

September 24 to October 1 | Barcelona,
Spain

5th Canadian Cancer Research Conference

November 3-5, 2019 | Ottawa, ON

**Multi-Disciplinary Gynecologic Oncology
Annual Lecture Series**

November 22, 2019 | Toronto, ON



SAVE THE DATE

**CAMO 2020 ANNUAL SCIENTIFIC MEETING
APRIL 30, 2020 | TORONTO, ON**

